Tocqueville Asset Management L.P. Macrogenics Inc Transaction History

Tocqueville Asset Management L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Feb 13, 2018	SELL	$16.19 - $20.3 $1.62 Million - $2.03 Million	-100,000 Closed	0 $0
Q3 2017 Oct 30, 2017	BUY	$15.52 - $18.94 $1.55 Million - $1.89 Million	100,000	100,000 $1.85 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.